Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
NICE changes its mind on Novartis’ Kisqali for breast cancerNICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England Share XNICE changes its mind on Novartis’ Kisqali for breast cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-kisqali-for-breast-cancer/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Roche closes on EU approval for Tecentriq in breast cancerRoche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of Share XRoche closes on EU approval for Tecentriq in breast cancerhttps://pharmaphorum.com/news/roche-closes-on-eu-approval-for-tecentriq-in-breast-cancer/
EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
MacroGenics looks to future with breast cancer drug margetuximabA small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its Share XMacroGenics looks to future with breast cancer drug margetuximabhttps://pharmaphorum.com/news/macrogenics-looks-to-future-with-breast-cancer-drug-margetuximab/
Novartis steals a march in CDK4/6 market with breast cancer dataNovartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in Share XNovartis steals a march in CDK4/6 market with breast cancer datahttps://pharmaphorum.com/news/novartis-market-breast-cancer-data-asco-2019/
Novartis scores first approval for PIK3CA breast cancer drugThe FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the Share XNovartis scores first approval for PIK3CA breast cancer drughttps://pharmaphorum.com/news/novartis-scores-first-approval-for-pik3ca-breast-cancer-drug/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
